Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Alnylam Pharmaceuticals (ALNY)

Alnylam Pharmaceuticals (ALNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 41,317,312
  • Shares Outstanding, K 133,428
  • Annual Sales, $ 3,714 M
  • Annual Income, $ 313,750 K
  • EBIT $ 502 M
  • EBITDA $ 557 M
  • 60-Month Beta 0.39
  • Price/Sales 11.50
  • Price/Cash Flow 114.49
  • Price/Book 53.59

Options Overview Details

View History
  • Implied Volatility 47.45% (+2.51%)
  • Historical Volatility 38.56%
  • IV Percentile 79%
  • IV Rank 70.86%
  • IV High 54.81% on 01/09/26
  • IV Low 29.56% on 08/13/25
  • Expected Move (DTE 25) 24.91 (8.04%)
  • Put/Call Vol Ratio 0.37
  • Today's Volume 653
  • Volume Avg (30-Day) 545
  • Put/Call OI Ratio 0.37
  • Today's Open Interest 22,521
  • Open Int (30-Day) 20,899
  • Expected Range 284.76 to 334.57

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 27 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $0.92
  • Number of Estimates 9
  • High Estimate $1.67
  • Low Estimate $0.53
  • Prior Year $-0.44
  • Growth Rate Est. (year over year) +309.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
299.62 +3.35%
on 03/24/26
343.36 -9.81%
on 04/14/26
-10.76 (-3.36%)
since 03/17/26
3-Month
298.00 +3.91%
on 02/12/26
376.87 -17.83%
on 01/22/26
-49.61 (-13.81%)
since 01/16/26
52-Week
228.28 +35.65%
on 04/21/25
495.55 -37.51%
on 10/20/25
+75.10 (+32.02%)
since 04/17/25

Most Recent Stories

More News
Alnylam to Webcast Conference Call Discussing First Quarter 2026 Financial Results

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2026 on Thursday,...

ALNY : 309.66 (-3.27%)
New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management

− Vutrisiran, which Silences Transthyretin at the Source, Shown to Improve Health-Related Quality-of-Life in Those with ATTR-CM, with Treatment Effects Comparable to Patients More than Ten Years Younger...

ALNY : 309.66 (-3.27%)
Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart Association

− Efforts Aimed at Facilitating Earlier Diagnosis, Coordinated Care, and Long-Term Patient Impact in ATTR-CM – − Alnylam to Host TTR Investor Webinar Today at 9:30...

ALNY : 309.66 (-3.27%)
Is Incyte Stock Outperforming the Dow?

Incyte has outperformed the Dow over the past year, and analysts are moderately optimistic about the stock’s prospects.

ALNY : 309.66 (-3.27%)
INCY : 97.82 (+2.62%)
$DOWI : 49,447.43 (+1.79%)
Alnylam to Webcast TTR Investor Webinar

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming TTR Investor Webinar on the Investors section of the Company’s...

ALNY : 309.66 (-3.27%)
Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics

Agreement Combines Tenaya’s Expertise in Identification and Validation of Genetic Heart Disease Targets with Alnylam’s Ability to Deliver Transformational Therapeutics Tenaya to Receive Up to...

TNYA : 0.7821 (+4.68%)
ALNY : 309.66 (-3.27%)
Alnylam to Webcast Presentation at TD Cowen 46th Annual Health Care Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the TD Cowen 46 th Annual...

ALNY : 309.66 (-3.27%)
Alnylam: Q4 Earnings Snapshot

Alnylam: Q4 Earnings Snapshot

ALNY : 309.66 (-3.27%)
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Period Progress

− Achieved Fourth Quarter and Full Year 2025 Global Net Product Revenues of $995 Million and $2,987 Million, Respectively, Representing 121% and 81% Growth Compared to Same Periods in 2024 – ...

ALNY : 309.66 (-3.27%)
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2025 Financial Results

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2025...

ALNY : 309.66 (-3.27%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Alnylam Pharmaceuticals Inc. is a development-stage biopharmaceutical company focused on the development of novel therapeutics based on RNA interference. The company's pipeline of experimental RNAi therapeutics is focused across three strategic therapeutic areas - genetic medicines, cardio-metabolic...

See More

Key Turning Points

3rd Resistance Point 342.66
2nd Resistance Point 334.59
1st Resistance Point 322.13
Last Price 309.66
1st Support Level 301.60
2nd Support Level 293.53
3rd Support Level 281.07

See More

52-Week High 495.55
Fibonacci 61.8% 393.45
Fibonacci 50% 361.91
Fibonacci 38.2% 330.38
Last Price 309.66
52-Week Low 228.28

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.